Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Alterity Therapeutics ( (AU:ATH) ).
Alterity Therapeutics announced that its CEO, David Stamler, will provide a corporate update during a Fireside Chat hosted by MST Access, focusing on the progress of the ATH434 development program for Multiple System Atrophy. This announcement follows the positive Phase 2 data released in January, highlighting the company’s ongoing efforts to advance its clinical trials and strengthen its position in the biotechnology industry, potentially impacting stakeholders and the market for neurodegenerative disease treatments.
More about Alterity Therapeutics
Alterity Therapeutics is a clinical stage biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, particularly Parkinson’s disease and related disorders. The company is advancing its lead asset, ATH434, which has shown positive results in Phase 2 trials for Multiple System Atrophy (MSA), a rare Parkinsonian disorder. Alterity operates from Melbourne, Australia, and San Francisco, USA, and has a broad drug discovery platform aimed at addressing neurological disease pathology.
YTD Price Performance: 10.0%
Average Trading Volume: 14,450,003
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$100.4M
For an in-depth examination of ATH stock, go to TipRanks’ Overview page.